Clin Mol Hepatol.
2020 Jan;26(1):70-73. 10.3350/cmh.2019.0026.
The management of polycystic liver disease by tolvaptan
- Affiliations
-
- 1Clinical Medical Sciences, Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan
- KMID: 2501318
- DOI: http://doi.org/10.3350/cmh.2019.0026
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
- Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
- Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
- Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
- Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan
